KR890012000A - 인간 b세포 자극인자-2에 대한 수용체 단백질 - Google Patents

인간 b세포 자극인자-2에 대한 수용체 단백질 Download PDF

Info

Publication number
KR890012000A
KR890012000A KR1019890000644A KR890000644A KR890012000A KR 890012000 A KR890012000 A KR 890012000A KR 1019890000644 A KR1019890000644 A KR 1019890000644A KR 890000644 A KR890000644 A KR 890000644A KR 890012000 A KR890012000 A KR 890012000A
Authority
KR
South Korea
Prior art keywords
protein
amino acid
dna
human
terminal
Prior art date
Application number
KR1019890000644A
Other languages
English (en)
Other versions
KR0144861B1 (ko
Inventor
다다미쯔 기시모토
Original Assignee
다다미쯔 기시모토
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27454721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890012000(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다다미쯔 기시모토 filed Critical 다다미쯔 기시모토
Publication of KR890012000A publication Critical patent/KR890012000A/ko
Priority to KR1019980005370A priority Critical patent/KR100255331B1/ko
Application granted granted Critical
Publication of KR0144861B1 publication Critical patent/KR0144861B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

내용 없음

Description

인간 B세포 자극인자-2에 대한 수용체 단백질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 세포가 BSF2-비오틴-아비딘을 경유 형광으로 염색되는 실험으로 형광 강도에 대한 세포의 빈도를 나타낸 그래프로서, 여기서, (A)는 음성 벡터로 감염된 세포로부터 얻은 결과를 나타내고, (B)는 본 발명의 CDNA을 함유하는 벡터로 감염된 세포로부터 얻은 결과를 나타내며, 그리고 (C)는 과잉의 BSF2의 존재하에서 상술한 양성적으로 감염된 세포를 비오틴화된 BSF2로 처리하여 얻은 결과를 나타내며, 제2도는 실시예 모노사이트 U937셀 라인에서 유도된 BSF2 슈용체에 대한 DNA서열 코팅을 함유하는 CDNA의 제한 효소 절단지도이며, 여기서 사선 부분은 번역 개시 코돈 ATG로 부터 번역 정지 코돈 TAG까지의 영역을 나타내며,

Claims (17)

  1. 인간 B세포 자극인자-2에 특이하게 결합할 수 있는, 인간 B세포 자극인자-2에 대한 분리된 수용체 단백질.
  2. 제1항에 있어서, 수용체 단백질이 다음 아미노산 서열(Ⅰ)을 갖는 단백질,
    (N-말단)
    (C-말단)
    천연 단백질의 생물학적 활성은 그대로 유지되면서 아미노산 서열(Ⅰ)로 부터 하나 또는 하나이상의 아미노산 잔기가 제거된 단백질, 천연 단백질의 생물학적 활성을 그대로 유지하면서 아미노산 서열(Ⅰ)에 한 또는 하나 이상의 아미노산 잔기가 가해진 단백질, 그리고 천연 단백질의 생물학적 활성은 그대로 유지하면서 하나 또는 하나 이상의 아미노산 잔기가 하나 또는 하나 이상의 다른 아미노산 잔기로 치환된 단백질 그룹으로 부터 선택된 분리된 단백질.
  3. 제2항에 있어서, 단백질이 아민산 서열(Ⅰ)로 부터 N-말단 부근의 아미노산 잔기가 제거된 서열을 갖는 분리된 단백질.
  4. 제3항에 있어서, 단백질이 다음 아미노산 서열(Ⅱ)을 갖는 분리된 단백질.
    (N-말단)
    (C-말단)
  5. 제2항에 있어서, 단백질이 아미노산 서열(Ⅰ)로 부터 C말단에서 아미노산 잔기가 제거된 서열을 갖는 분리된 단백질.
  6. 제5항에 있어서, 단백질이 다음의 아미노산 서열(Ⅲ)을 갖는 분리된 단백질.
    (N-말단)
    (C-말단)
  7. 제5항에 있어서, 단백질이 다음의 아미노산 서열(Ⅳ)을 갖는 분리된 단백질.
    (N-말단)
    (C-말단)
  8. 제1항에서 정의한 단백질에 대한 DNA 코딩.
  9. 제2항에서 정의한 단백질에 대한 DNA 코딩.
  10. 제9항에 있어서, DNA가 다음의 뉴클레오티드의 서열(Ⅴ)는 갖는 DNA.
    (5′-말단)
    (′-말단)
  11. 제3항 내지 7항중 어느 하나에 따른 단백질에 대한 DNA 코딩.
  12. 제8항에 있어서, DNA가 이 DNA의 발현을 조절하는 다른 DNA서열에 작동적으로 결합되는 DNA.
  13. 인간 B세포 자극인자-2에 특이하게 결합할 수 있는 인간 B세포자극인자-2-에 대한 수용체 단백질의 DNA 코딩을 함유하는 발현 벡터.
  14. 제13항에 따른 발현 벡터로 형질전화된 숙주 생물.
  15. 수용체 단백질을 생산하기 위해 배지중에서 제7항에 따른 숙주 생물을 배양하고 배양물로부터 수용체 단백질을 회수하는 것으로 이루어진, 인간 B세포 자극인자-2를 특히하게 결합할 수 있는, 인간 B세포 자극인자-2에 대한 수용체 단백질의 생산 방법.
  16. 제1항 내지 제7항중 어느 하나에 따른 단백질과 특이하게 반응 할수 있는 항체.
  17. 제16항에 따른 항체를 생산할 수 있는 히브리도마.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890000644A 1988-01-22 1989-01-21 인간 b세포 자극인자-2에 대한 수용체 단백질 KR0144861B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980005370A KR100255331B1 (ko) 1988-01-22 1998-02-17 인간 b세포 자극인자-2에 대한 수용체 단백질에 특이적인 항체 및 이를 생산하는 하이브리도마

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP88-012387 1988-01-22
JP1238788 1988-01-22
JP88-012599 1988-01-25
JP1259988 1988-01-25
JP19488588 1988-08-04
JP88-194885 1988-08-04
JP746189 1989-01-14
JP89-7461 1989-01-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019980005370A Division KR100255331B1 (ko) 1988-01-22 1998-02-17 인간 b세포 자극인자-2에 대한 수용체 단백질에 특이적인 항체 및 이를 생산하는 하이브리도마

Publications (2)

Publication Number Publication Date
KR890012000A true KR890012000A (ko) 1989-08-23
KR0144861B1 KR0144861B1 (ko) 1998-07-01

Family

ID=27454721

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890000644A KR0144861B1 (ko) 1988-01-22 1989-01-21 인간 b세포 자극인자-2에 대한 수용체 단백질

Country Status (11)

Country Link
US (5) US5171840A (ko)
EP (1) EP0325474B1 (ko)
JP (1) JP2865300B2 (ko)
KR (1) KR0144861B1 (ko)
AT (1) ATE123295T1 (ko)
AU (1) AU615715B2 (ko)
CA (1) CA1341152C (ko)
DE (1) DE68922869T2 (ko)
ES (1) ES2072892T3 (ko)
HK (1) HK49997A (ko)
IL (1) IL89011A (ko)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (en) * 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
ATE144713T1 (de) * 1989-07-20 1996-11-15 Tadamitsu Kishimoto Antikörper gegen menschlichen interleukin-6- rezeptor
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
WO1994025036A1 (en) * 1993-04-30 1994-11-10 Chugai Seiyaku Kabushiki Kaisha Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor
US5578301A (en) * 1993-12-14 1996-11-26 Sandoz Ltd. Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
US5599536A (en) * 1993-12-13 1997-02-04 Sandoz Ltd. Method for suppressing the acute phase response in a patient receiving IL-6 therapy
US5518882A (en) * 1993-12-21 1996-05-21 Biotex Laboratories, Inc. Immunological methods of component selection and recovery
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
PL186506B1 (pl) 1994-10-07 2004-01-30 Chugai Pharmaceutical Co Ltd Sposób wytwarzania środka farmaceutycznego hamującego wzrost komórek błony maziowej i zastosowanie monoklonalnego przeciwciała
CN101829325A (zh) 1994-10-21 2010-09-15 岸本忠三 Il-6受体的抗体在制备药物组合物中的用途
WO1996018416A1 (fr) * 1994-12-16 1996-06-20 Chugai Seiyaku Kabushiki Kaisha Inhibiteur d'expression contre le recepteur humain de l'interleukine-6
JP3458512B2 (ja) 1995-02-23 2003-10-20 東ソー株式会社 骨密度の変動推定方法又は骨そしょう症の診断方法及びこれに用いる試薬キット
KR100838862B1 (ko) 1997-03-21 2008-06-16 츄가이 세이야꾸 가부시키가이샤 아이엘-6 안타고니스트를 유효성분으로 함유하는 감작 티 세포 관여 질환의 예방 또는 치료제
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
PT1004315E (pt) 1997-08-15 2008-07-09 Chugai Pharmaceutical Co Ltd Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico
CN100374159C (zh) * 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
WO2001016166A2 (en) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
KR101080021B1 (ko) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
JPWO2005090405A1 (ja) 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JPWO2007061029A1 (ja) 2005-11-25 2009-05-07 学校法人慶應義塾 前立腺癌治療剤
WO2007086490A1 (ja) 2006-01-27 2007-08-02 Keio University 脈絡膜血管新生を伴う疾患の治療剤
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
BRPI0712224B8 (pt) 2006-06-02 2021-05-25 Regeneron Pharma anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CL2008000188A1 (es) 2007-01-23 2008-07-18 Chugai Pharmaceutical Co Ltd Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
EP3246045A1 (en) 2007-07-26 2017-11-22 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
BRPI0817482B8 (pt) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
EP2217264B8 (en) * 2007-11-28 2013-02-27 Hadasit Medical Research Services and Development Ltd. Use of an il-6/il-6 receptor complex for preventing xerostomia induced by radiotherapy or chemotherapy
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AU2009246430B2 (en) 2008-05-13 2015-07-02 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP2460538B1 (en) 2009-07-31 2017-09-13 Shin Maeda Cancer metastasis inhibitor
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
KR20200059320A (ko) 2010-11-08 2020-05-28 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CA2849195A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
AU2015334984A1 (en) 2014-10-21 2017-04-13 Ablynx Nv Treatment of IL-6R related diseases
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
MA42657A (fr) 2015-08-18 2018-06-27 Regeneron Pharma Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLE FOR THE DELIVERY OF CHEMOPREVENTIVE AGENTS
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
JP7458790B2 (ja) 2018-01-31 2024-04-01 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2020047029A1 (en) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
MX2023010491A (es) 2021-03-12 2023-09-18 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124697A (ja) * 1984-07-11 1986-02-03 Tanaka Kikai Sangyo Kk 船舶における圧力流体の冷却方法
AU8270187A (en) * 1986-10-28 1988-05-25 Memorial Sloan-Kettering Cancer Center Dna expressing fc receptor protein
JPS649774A (en) * 1987-07-02 1989-01-13 Fujitsu Ltd Thermal transfer printing method
JP2629712B2 (ja) * 1987-07-03 1997-07-16 日東紡績株式会社 インクジェット記録用紙
JP2598666B2 (ja) * 1987-10-19 1997-04-09 忠三 岸本 抗ヒトｂｃｄｆモノクローナル抗体
CA1341152C (en) * 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2

Also Published As

Publication number Publication date
AU615715B2 (en) 1991-10-10
EP0325474A2 (en) 1989-07-26
KR0144861B1 (ko) 1998-07-01
IL89011A (en) 1995-03-15
US5171840A (en) 1992-12-15
DE68922869T2 (de) 1995-10-19
ES2072892T3 (es) 1995-08-01
US5990282A (en) 1999-11-23
IL89011A0 (en) 1989-08-15
EP0325474B1 (en) 1995-05-31
DE68922869D1 (de) 1995-07-06
US5851793A (en) 1998-12-22
HK49997A (en) 1997-04-25
AU2872089A (en) 1989-07-27
US6410691B1 (en) 2002-06-25
EP0325474A3 (en) 1990-06-06
US5480796A (en) 1996-01-02
ATE123295T1 (de) 1995-06-15
CA1341152C (en) 2000-12-12
JPH02288898A (ja) 1990-11-28
JP2865300B2 (ja) 1999-03-08

Similar Documents

Publication Publication Date Title
KR890012000A (ko) 인간 b세포 자극인자-2에 대한 수용체 단백질
US6251635B1 (en) Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
C. Schröder et al. Stimulation of protein (collagen) synthesis in sponge cells by a cardiac myotrophin‐related molecule from Suberites domuncula
EP1806402A3 (en) CTLA4/CD28 ligands and uses therefor
JPH02500876A (ja) 組換えポリペプチドの製品およびその製造、単離および精製方法
MD2311F2 (en) Obesity polypeptides, immunogenic fragment, analogue, human analogue and reduced human analogue, isolated molecule of nucleic acid, DNA molecule, detectable marked molecule of nucleic acid, vectors containing said DNA molecule, monoclonal antibody, polyclonal antibody and pharmaceutical composition for reduction of the animals body weight
EA199700329A1 (ru) Новый белок и способ его получения
RU2005136013A (ru) Фосфодиэстераза 8а
ATE121776T1 (de) Expression des biologisch aktiven faktors xiii.
RU2218181C2 (ru) ЧЕЛОВЕЧЕСКИЙ СЕМАФОРИН L(H-Sema-L) И СООТВЕТСТВУЮЩИЕ СЕМАФОРИНЫ В ДРУГИХ ВИДАХ
ATE338113T1 (de) Transferrin-rezeptor gene von haemophilus
CA2288373A1 (en) Human cerberus protein
KR900014428A (ko) 신규폴리펩타이드 및 그 제조방법
EP0546074A4 (en) Genetic material encoding igfbp-5
KR910006483A (ko) 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
Schleicher et al. Isolation and characterization of calmodulin from the motile green alga Chlamydomonas reinhardtii
ATE253639T1 (de) Verfahren zur herstellung von peptiden
EA199600001A3 (ru) Агент экстракции периплазматических рекомбинантных белков, способ экстракции периплазматического белка и способ культивирования прокариотического микроорганизма
US6228631B1 (en) Recombinant α-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
NO874704L (no) Minaktivin fremstilt ved rekombinant dna-teknikk.
RU2000111744A (ru) Очищенная и выделенная днк, химерный полинуклеотид, вектор экспрессии и клетка-хозяин
KR930701464A (ko) 이질성 단백질의 생성용 스트렙토마이세스 벡터
JP2670104B2 (ja) 蛋白質の分泌発現
ATE415422T1 (de) Menschliches gas-6 (growth arrest-specific gene 6) protein und dafür kodierende nukleinsäuren
EP0694081A1 (en) RECOMBINANT $g(a)-N-ACETYLGALACTOSAMINIDASE ENZYME AND cDNA ENCODING SAID ENZYME

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120418

Year of fee payment: 15

EXPY Expiration of term